Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan J Darrow

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
BMJ (Clinical Research Ed.)|September 25, 2015
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort studyAaron S Kesselheim, Bo Wang, Jessica M Franklin, et al.
Clinical and Translational Science|May 13, 2021
The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020Sunand Kannappan, Jonathan J Darrow, Aaron S Kesselheim, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 6, 2020
Origins and Ownership of Remdesivir: Implications for PricingChangWon C Lee, Jonathan J Darrow, Jerry Avorn, et al.
Therapeutic Innovation & Regulatory Science|September 5, 2023
Prioritizing Early Disease InterventionH Hugo Caicedo, Jonathan J Darrow, Julio C Caicedo, et al.
Clinical Pharmacology and Therapeutics|May 28, 2021
Assessing the Impact of US Food and Drug Administration Breakthrough Therapy Designation Timing on Trial Characteristics and Development SpeedLisette Pregelj, Damian C Hine, Aaron S Kesselheim, et al.
Journal of General Internal Medicine|February 9, 2022
Experts' Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient CareSanket S Dhruva, Jonathan J Darrow, Aaron S Kesselheim, et al.
Clinical Pharmacology and Therapeutics|November 12, 2018
The US Biosimilar Market: Stunted Growth and Possible ReformsAmeet Sarpatwari, Rachel Barenie, Gregory Curfman, et al.
Nature Biotechnology|September 13, 2024
The prevalence of post-NDA drug patents and their relationship to the timing of generic approvalJonathan J Darrow, Victor Van de Wiele, Beatrice Brown, et al.
Therapeutic Innovation & Regulatory Science|February 11, 2026
Ensuring Integrity of the Medicaid Drug Rebate ProgramPriyanka A Abraham, Joseph T Kannarkat, Benjamin N Rome, et al.
Clinical Pharmacology and Therapeutics|March 16, 2022
Strategies to Manage Drugs and Devices Approved Based on Limited Evidence: Results of a Modified Delphi PanelSanket S Dhruva, Jonathan J Darrow, Aaron S Kesselheim, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
BMJ (Clinical Research Ed.)|September 25, 2015
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort studyAaron S Kesselheim, Bo Wang, Jessica M Franklin, et al.
Clinical and Translational Science|May 13, 2021
The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020Sunand Kannappan, Jonathan J Darrow, Aaron S Kesselheim, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 6, 2020
Origins and Ownership of Remdesivir: Implications for PricingChangWon C Lee, Jonathan J Darrow, Jerry Avorn, et al.
Therapeutic Innovation & Regulatory Science|September 5, 2023
Prioritizing Early Disease InterventionH Hugo Caicedo, Jonathan J Darrow, Julio C Caicedo, et al.
Clinical Pharmacology and Therapeutics|May 28, 2021
Assessing the Impact of US Food and Drug Administration Breakthrough Therapy Designation Timing on Trial Characteristics and Development SpeedLisette Pregelj, Damian C Hine, Aaron S Kesselheim, et al.
Journal of General Internal Medicine|February 9, 2022
Experts' Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient CareSanket S Dhruva, Jonathan J Darrow, Aaron S Kesselheim, et al.
Clinical Pharmacology and Therapeutics|November 12, 2018
The US Biosimilar Market: Stunted Growth and Possible ReformsAmeet Sarpatwari, Rachel Barenie, Gregory Curfman, et al.
Nature Biotechnology|September 13, 2024
The prevalence of post-NDA drug patents and their relationship to the timing of generic approvalJonathan J Darrow, Victor Van de Wiele, Beatrice Brown, et al.
Therapeutic Innovation & Regulatory Science|February 11, 2026
Ensuring Integrity of the Medicaid Drug Rebate ProgramPriyanka A Abraham, Joseph T Kannarkat, Benjamin N Rome, et al.
Clinical Pharmacology and Therapeutics|March 16, 2022
Strategies to Manage Drugs and Devices Approved Based on Limited Evidence: Results of a Modified Delphi PanelSanket S Dhruva, Jonathan J Darrow, Aaron S Kesselheim, et al.
Pageof 9